Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

89.68 +1.87 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings) ↗
 
Via Benzinga
News headline image
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Company to provide update on its emerging pipeline of high-value immunology programs 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Analyst Expectations for Kymera Therapeutics's Future ↗
 
Via Benzinga
News headline image
Preview: Kymera Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Expert Ratings for Kymera Therapeutics ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
What 5 Analyst Ratings Have To Say About Kymera Therapeutics ↗
 
Via Benzinga
News headline image
More Than $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed slightly higher on Monday, there were a few notable insider trades. 
Via Benzinga
News headline image
HC Wainwright & Co. Maintains Buy Rating for Kymera Therapeutics: Here's What You Need To Know ↗
 
Via Benzinga
News headline image
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
The dosing of the first patient in the Phase 2 Atopic Dermatitis (AD) clinical trial is expected later this quarter 
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Third Quarter 2023 Financial Results on November 2
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why CalAmp Shares Are Trading Lower By Around 32%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Why Shares of Kymera Therapeutics Jumped on Tuesday ↗
The company had a big bounce after hitting a 52-week low the day before. 
Via The Motley Fool
News headline image
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday ↗
Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to... 
Via Benzinga
News headline image
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023 ↗
 
Via Benzinga
News headline image
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
From Kymera Therapeutics, Inc.
Via GlobeNewswire
News headline image
Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413
From Kymera Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.